August 16, 2023 03:07 PM EDT
Pharma

Mallinck­rodt con­sid­ers Chap­ter 11 as ‘ad­vanced dis­cus­sions’ con­tin­ue

Paul Schloesser

Associate Editor

Mallinck­rodt is con­sid­er­ing fil­ing for Chap­ter 11 bank­rupt­cy for the sec­ond time in three years as it again de­lays mak­ing a pay­ment re­quired as part …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times